INBS icon

Intelligent Bio Solutions

1.78 USD
-0.05
2.73%
At close Jul 3, 4:00 PM EDT
After hours
1.78
+0.00
0.00%
1 day
-2.73%
5 days
7.88%
1 month
11.25%
3 months
24.48%
6 months
20.27%
Year to date
26.24%
1 year
-3.26%
5 years
-99.93%
10 years
-99.93%
 

About: Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).

Employees: 48

0
Funds holding %
of 7,310 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

1,074% more capital invested

Capital invested by funds: $108K [Q4 2024] → $1.26M (+$1.16M) [Q1 2025]

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

13% more funds holding

Funds holding: 8 [Q4 2024] → 9 (+1) [Q1 2025]

11.19% more ownership

Funds ownership: 1.75% [Q4 2024] → 12.94% (+11.19%) [Q1 2025]

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Research analyst outlook

We haven’t received any recent analyst ratings for INBS.

Financial journalist opinion

Based on 4 articles about INBS published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Fingerprint Drug Testing Across Scandinavia
With over 450 accounts across 24 countries, INBS continues to advance the evolution of drug screening technology With over 450 accounts across 24 countries, INBS continues to advance the evolution of drug screening technology
Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Fingerprint Drug Testing Across Scandinavia
Neutral
GlobeNewsWire
2 weeks ago
Intelligent Bio Solutions Launches In-House Fingerprint Drug Testing Across 20+ Sites for Major Australian Waste Operator, Accelerating APAC Expansion
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Managed Waste Service (“MWS”), a leading Australian waste management provider, plans to implement INBS' Intelligent Fingerprinting Drug Screening System across its New South Wales operations, including its land clearing and green waste processing sites.
Intelligent Bio Solutions Launches In-House Fingerprint Drug Testing Across 20+ Sites for Major Australian Waste Operator, Accelerating APAC Expansion
Positive
Zacks Investment Research
2 weeks ago
INBS Stock May Rise on SMARTOX Partnership Expanding Forensic Reach
Intelligent Bio Solutions collaborates with SMARTOX to expand U.S. forensic reach, boosting its drug test tech and eyeing FDA clearance for growth.
INBS Stock May Rise on SMARTOX Partnership Expanding Forensic Reach
Neutral
GlobeNewsWire
3 weeks ago
Intelligent Bio Solutions Expands U.S. Forensic Market Presence, Seeks FDA Clearance for Breakthrough Fingerprint Drug Testing
SMARTOX has deployed over 50 of INBS' Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including more than 1,500 tests in 2024 alone
Intelligent Bio Solutions Expands U.S. Forensic Market Presence, Seeks FDA Clearance for Breakthrough Fingerprint Drug Testing
Neutral
GlobeNewsWire
1 month ago
Intelligent Bio Solutions to Showcase Fingerprint Drug Testing at RISE25 Conference from May 28-31, Supporting Innovation in U.S. Forensic Drug Testing
INBS to participate with U.S. distribution partner SMARTOX at RISE25, the leading U.S. conference on addiction, mental health, and justice innovation which draws over 7,000 attendees annually
Intelligent Bio Solutions to Showcase Fingerprint Drug Testing at RISE25 Conference from May 28-31, Supporting Innovation in U.S. Forensic Drug Testing
Neutral
GlobeNewsWire
1 month ago
Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing Capabilities in Remote Queensland Workforce Deployment
Completion of 160 tests conducted in less than 90 minutes demonstrates a level of speed and efficiency beyond the limits of traditional testing approaches Completion of 160 tests conducted in less than 90 minutes demonstrates a level of speed and efficiency beyond the limits of traditional testing approaches
Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing Capabilities in Remote Queensland Workforce Deployment
Neutral
GlobeNewsWire
1 month ago
Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing
Company surpasses 450 accounts across 24 countries as global demand for fingerprint drug testing surges Company surpasses 450 accounts across 24 countries as global demand for fingerprint drug testing surges
Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing
Neutral
GlobeNewsWire
1 month ago
Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements
20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025  35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended March 31, 2025, and provided a business update.   The Company delivered a strong quarter of growth in revenue compared to the previous quarter, supported by ongoing expansion across safety-critical industries and steady customer acquisition.
Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements
Neutral
GlobeNewsWire
1 month ago
Intelligent Bio Solutions Drives Global Growth Through Multilingual Digital Expansion
Arabic, Italian, and Spanish-language websites unlock commercial access to regions representing over 1.4 billion people Multilingual rollout aligns with product readiness and accelerates international sales pipeline development NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the launch of three new localized websites in Arabic, Italian, and Spanish. This rollout supports the Company's global growth plans and international sales expansion by opening digital and commercial access to some of the world's fastest-growing, high-demand regions for workplace safety and compliance solutions.
Intelligent Bio Solutions Drives Global Growth Through Multilingual Digital Expansion
Neutral
GlobeNewsWire
2 months ago
Intelligent Bio Solutions Expands Global Reach with Latin American Spanish Language Integration into Drug Screening System
Company expands Intelligent Fingerprinting Drug Screening System multilingual capabilities to meet growing demand across Latin American Spanish-speaking markets
Intelligent Bio Solutions Expands Global Reach with Latin American Spanish Language Integration into Drug Screening System
Charts implemented using Lightweight Charts™